Home > Neurology > AAN 2022 > Muscle and Neuro-Muscular Disorders > Ravulizumab in patients with generalised myasthenia gravis

Ravulizumab in patients with generalised myasthenia gravis

Presented By
Dr Tuan Hoang Vu, University of South Florida Physicians Group, FL, USA
Presented by
Tuan Hoang Vu University of South Florida
AAN 2022
In the randomised, phase 3 CHAMPION MG trial, the terminal complement component 5 (C5) inhibitor ravulizumab provided rapid and sustained symptomatic improvements in patients with generalised myasthenia gravis (MG) for up to 26 weeks. These effects were sustained after 26 weeks of open-label treatment. In most (~85%) generalised MG patients, binding auto-antibodies to the post-synaptic acetylcholine receptor (AChR) leads to activation of the complement cascade and generation of the membrane attack complex (MAC), resulting in the destruction of the post-synaptic membrane of the neuromuscular junction [1]. Treatment with a complement inhibitor led to significant improvements of symptoms in patients with refractory generalised MG [2]. The phase 3 CHAMPION MG trial (NCT03920293) enrolled 175 patients with AChR antibody-positive (AChR Ab+) generalised M...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on